Can urinary PCA3 Supplement PSA in the early detection of prostate cancer?

noticia |

Wei J.T., Feng Z., Partin A.W., Brown E., Thompson I., Sokoll L., Chan D.W., Lotan Y., Kibel A.S., Busby J.E., Bidair M., Lin D.W., Taneja S.S., Viterbo R., Joon A.Y., Dahlgren J., Kagan J., Srivastava S., Sanda M.G.

Journal of Clinical Oncology 2014 32:36 (4066-4072)

Purpose: Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA. Patients and Methods: In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score >60) and the negative predictive value (NPV) for a repeat biopsy (at a score <20). Results: For the detection of any cancer, PPV was…(vermás)


1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)